Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Review, H1 2016', provides in depth analysis on Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted pipeline therapeutics. The report provides comprehensive information on the Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - The report reviews Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics and enlists all their major and minor projects - The report assesses Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Overview 6 Therapeutics Development 7 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Stage of Development 7 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Therapy Area 8 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Indication 9 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Companies 12 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Products under Development by Universities/Institutes 14 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Companies Involved in Therapeutics Development 22 Cerecor Inc. 22 CureVac GmbH 23 Eisai Co., Ltd. 24 Inovio Pharmaceuticals, Inc. 25 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Drug Profiles 26 CV-9103 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 E-2072 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 INO-5150 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecule for Neuropathic Pain - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Dormant Projects 33 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Discontinued Products 35 Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) - Featured News & Press Releases 36 Jul 27, 2015: Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer 36 Jul 07, 2015: CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer 36 Nov 19, 2012: Experimental Drug Improves Memory In Mice With Multiple Sclerosis, Researchers Report 37 Jun 10, 2011: CureVac Presents Promising New Data For Prostate Cancer Vaccine CV9103 At ASCO Conference 39 Feb 02, 2011: Inovio's Dual-Antigen SynCon DNA Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial 40 Oct 04, 2010: CureVac Presents Data From Phase I/IIa Clinical Study With CV9103 In Hormone-Refractory Prostate Cancer 40 Nov 02, 2009: CureVac Launches Phase IIa mRNA Vaccine Trial In Prostate Cancer 41 May 01, 2009: CureVac Receives FDA Approval to Start its Phase I / IIa Trial in the U.S. with an mRNA Vaccine for the Treatment of Prostate Cancer 41 Jan 05, 2009: CureVac Receives IND Approval From FDA To Start Its Phase I/IIa mRNA Vaccine Clinical Trial In Prostate Cancer 42 Oct 12, 2008: CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Cerecor Inc., H1 2016 22 Pipeline by CureVac GmbH, H1 2016 23 Pipeline by Eisai Co., Ltd., H1 2016 24 Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 25 Dormant Projects, H1 2016 33 Dormant Projects (Contd..1), H1 2016 34 Discontinued Products, H1 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
